Search

Boulder-based Clovis Oncology, a developer of anti-cancer drugs, has filed for an IPO, saying that it is looking to raised up to $149.5M on the public markets. The firm has applied to list on the NASDAQ GLobal Market as CLVS. The firm's IPO is being underwritten by J.P. Morgan, Credit Suisse, and Leerink Swan. Clovis Oncology is venture backed by : Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth Bioventures, Frazier Healthcare Ventures, Pfizer, and ProQuest Investments.
posted on Thursday, June 23, 2011

Related companies:
Clovis Oncology

Related stories:
> Clovis Oncology Prices IPO
> Clovis Oncology Raises $130M In IPO
> Clovis Oncology On Tap For IPO
> Clovis Oncology Raising $170M in Public Offering
> Clovis Oncology Raises $145M

---

Techrockies.com Home